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background: Congestion is the primary reason for heart failure hospitalizations (HFH). Recent telemonitoring strategies to detect congestion and 
prevent HFH using weights have not improved patient outcomes. The CHAMPION trial found significant reductions in HFH in patients whose syndrome 
was managed using pulmonary artery pressure (PAP) from an implantable hemodynamic monitor (IHM). While hemodynamic guided management 
reduced HFH, the impact on other causes of rehospitalizations is unknown.
Methods: CHAMPION was a prospective, randomized, single-blind study in previously hospitalized patients with NYHA class III HF. 550 patients 
were implanted with the IHM device and randomized to HF medical management with access to PAP (270) or to usual management (280). Average 
patient follow-up was 18 months. All hospitalizations and deaths were adjudicated by a blinded committee.
results: Total rehospitalizations were significantly reduced with IHM-guided care although only 38% were for primary HF diagnosis. For 100 
patients treated, 29 events of death or rehospitalizations could be prevented per year.
conclusion: Patient management enhanced through PAP monitoring not only reduces HFH, but also leads to significant reductions in death and all 
cause rehospitalizations. 
Clinical Endpoint
Treatment
(n=270)
Control
(n=280)
Absolute 
Reduction
Relative 
Reduction
Hazard Ratio
(95% CI)
p-value
Number Needed 
to Treat (NNT) to 
Prevent 1 Event Per 
Year
Events Reduced 
Per Year Per 100 
Patients Treated
HF Rehospitalizations 182 279 97
0.67
(0.55 - 0.80)
<0.0001 4 23
All Cause Rehospitalizations 554 672 118
0.84
(0.75 - 0.95)
0.0032 4 26
Death or All Cause 
Rehospitalizations
604 736 132
0.84
(0.76 - 0.94)
0.0017 3 29
